CorPath GRX STEMI Study

An Evaluation of Performance of the CorPath® GRX System in Robotic-PCI During Acute STEMI

This study will evaluate the performance of the CorPath GRX System in Robotic Primary PCI (RPPCI) in the treatment of ST-elevated myocardial infarction (STEMI).

This is a prospective, post-market, single-arm, multi-center, observational study to evaluate the performance of the CorPath GRX System during robotic-PCI for acute ST elevation myocardial infarction (STEMI).

Inclusion Criteria:

• Age ≥18 and ≤ 80 years
• Patients with STEMI<12 h of symptom onset
• Patient deemed appropriate for robotic-assisted PCI
• The subject has been informed of the nature of the study, agrees to its provisions, and has provided written consent

Exclusion Criteria:

Cardiogenic shock

• Cardiac arrest
• Need for manual or mechanical thrombectomy
• Failure/inability/unwillingness to provide informed consent
• The Investigator determines that the subject or the coronary anatomy is not suitable for robotic-assisted primary PCI treatment